-
1
-
-
84876149257
-
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
-
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-1342.
-
(2013)
Hepatology.
, vol.57
, Issue.4
, pp. 1333-1342
-
-
Mohd Hanafiah, K.1
Groeger, J.2
Flaxman, A.D.3
Wiersma, S.T.4
-
2
-
-
59149083248
-
The history of the "natural history" of hepatitis C (1968-2009)
-
Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99.
-
(2009)
Liver Int.
, vol.29
, Issue.SUPPL. 1
, pp. 89-99
-
-
Seeff, L.B.1
-
3
-
-
10744225097
-
Global burden of disease (GBD) for hepatitis C
-
World Health Organization
-
World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20-29.
-
(2004)
J Clin Pharmacol.
, vol.44
, Issue.1
, pp. 20-29
-
-
-
4
-
-
34250679750
-
Epidemiology of hepatitis C virus infection
-
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-2441.
-
(2007)
World J Gastroenterol.
, vol.13
, Issue.17
, pp. 2436-2441
-
-
Alter, M.J.1
-
5
-
-
84455209550
-
HCV routes of transmission: What goes around comes around
-
Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31(4):340-346.
-
(2011)
Semin Liver Dis.
, vol.31
, Issue.4
, pp. 340-346
-
-
Alter, M.J.1
-
6
-
-
79953168791
-
Virová hepatitida C. [Hepatitis C virus]
-
Czech
-
Urbánek P. Virová hepatitida C. [Hepatitis C virus]. Adiktologie. 2010;10(2):102-109. Czech.
-
(2010)
Adiktologie.
, vol.10
, Issue.2
, pp. 102-109
-
-
Urbánek, P.1
-
7
-
-
78751610017
-
Hidden hazards of HCV transmission
-
Czech
-
Pondé RA. Hidden hazards of HCV transmission. Med Microbiol Immunol. 2011;200(1):7-11. Czech.
-
(2011)
Med Microbiol Immunol.
, vol.200
, Issue.1
, pp. 7-11
-
-
Pondé, R.A.1
-
8
-
-
34548489173
-
Global estimates of prevalence of HCV infection among injecting drug users
-
Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-358.
-
(2007)
Int J Drug Policy.
, vol.18
, Issue.5
, pp. 352-358
-
-
Aceijas, C.1
Rhodes, T.2
-
9
-
-
80051676859
-
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews
-
Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583.
-
(2011)
Lancet.
, vol.378
, Issue.9791
, pp. 571-583
-
-
Nelson, P.K.1
Mathers, B.M.2
Cowie, B.3
-
10
-
-
33845438736
-
-
European Monitoring Centre for Drugs and Drug Addiction; Annual Report 2012., Luxembourg: Publications Office of the European Union, Available from:, Accessed September 1, 2013
-
European Monitoring Centre for Drugs and Drug Addiction; Annual Report 2012. The State of the Drugs Problem in Europe. Luxembourg: Publications Office of the European Union; 2012. Available from: http://www.emcdda.europa.eu/...cfm/att_190854_EN_TDAC12001ENC_.pdf. Accessed September 1, 2013.
-
(2012)
The State of the Drugs Problem in Europe
-
-
-
11
-
-
33748114343
-
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
-
Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4): 529-538.
-
(2006)
J Hepatol.
, vol.45
, Issue.4
, pp. 529-538
-
-
Perz, J.F.1
Armstrong, G.L.2
Farrington, L.A.3
Hutin, Y.4
Bell, B.5
-
12
-
-
43349090325
-
Limited uptake of hepatitis C treatment among injection drug users
-
Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126-133.
-
(2008)
J Community Health.
, vol.33
, Issue.3
, pp. 126-133
-
-
Mehta, S.H.1
Genberg, B.L.2
Astemborski, J.3
-
13
-
-
63549098520
-
Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents
-
Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16(5):352-358.
-
(2009)
J Viral Hepat.
, vol.16
, Issue.5
, pp. 352-358
-
-
Grebely, J.1
Raffa, J.D.2
Lai, C.3
-
14
-
-
20144388125
-
Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users
-
Strathdee S, Latka M, Campbell J, et al. Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005;40 Suppl 5:S304-S312.
-
(2005)
Clin Infect Dis.
, vol.40
, Issue.SUPPL. 5
-
-
Strathdee, S.1
Latka, M.2
Campbell, J.3
-
15
-
-
84859650825
-
-
Sydney, Australia: Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Available from:, Accessed September 1, 2013
-
Iversen J, Topp LJ, Maher L. Australian NSP Survey National Data Report 1995-2010. Sydney, Australia: Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales; 2011. Available from: http://www.kirby.unsw.edu.au/node/201260281. Accessed September 1, 2013.
-
(2011)
Australian NSP Survey National Data Report 1995-2010
-
-
Iversen, J.1
Topp, L.J.2
Maher, L.3
-
16
-
-
33644875265
-
Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies
-
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34-41.
-
(2006)
J Viral Hepat.
, vol.13
, Issue.1
, pp. 34-41
-
-
Micallef, J.M.1
Kaldor, J.M.2
Dore, G.J.3
-
17
-
-
43549109840
-
Acute hepatitis C: A systematic review
-
Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103(5):1283-1297.
-
(2008)
Am J Gastroenterol.
, vol.103
, Issue.5
, pp. 1283-1297
-
-
Kamal, S.M.1
-
18
-
-
81055140960
-
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort
-
van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011;6(11):e27555.
-
(2011)
PLoS One.
, vol.6
, Issue.11
-
-
van den Berg, C.H.1
Grady, B.P.2
Schinkel, J.3
-
19
-
-
84860297348
-
International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine
-
Grebely J, Prins M, Hellard M, et al. International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5): 408-414.
-
(2012)
Lancet Infect Dis.
, vol.12
, Issue.5
, pp. 408-414
-
-
Grebely, J.1
Prins, M.2
Hellard, M.3
-
20
-
-
78650806908
-
Future hepatitis C virus treatment: Interferon-sparing combinations
-
Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31 Suppl 1:62-67.
-
(2011)
Liver Int.
, vol.31
, Issue.SUPPL. 1
, pp. 62-67
-
-
Gane, E.1
-
21
-
-
75149163334
-
Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
-
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-521.
-
(2010)
Gastroenterology.
, vol.138
, Issue.2
, pp. 513-521
-
-
Davis, G.L.1
Alter, M.J.2
El-Serag, H.3
Poynard, T.4
Jennings, L.W.5
-
22
-
-
77955305804
-
The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression
-
John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010;53(2): 245-251.
-
(2010)
J Hepatol.
, vol.53
, Issue.2
, pp. 245-251
-
-
John-Baptiste, A.1
Krahn, M.2
Heathcote, J.3
Laporte, A.4
Tomlinson, G.5
-
24
-
-
84455182283
-
What is killing people with hepatitis C virus infection?
-
Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4):331-339.
-
(2011)
Semin Liver Dis.
, vol.31
, Issue.4
, pp. 331-339
-
-
Grebely, J.1
Dore, G.J.2
-
25
-
-
0034120427
-
Clinical significance of hepatitis C virus genotypes
-
Nizar NZ. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-235.
-
(2000)
Clin Microbiol Rev.
, vol.13
, Issue.2
, pp. 223-235
-
-
Nizar, N.Z.1
-
26
-
-
0030338551
-
Hepatitis C virus: Biological and clinical consequences of genetic heterogeneity
-
Cooreman MP, Schoondermark-Van de Ven EM. Hepatitis C virus: biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol Suppl. 1996;218:106-115.
-
(1996)
Scand J Gastroenterol
, vol.218
, Issue.SUPPL.
, pp. 106-115
-
-
Cooreman, M.P.1
Schoondermark-Van de Ven, E.M.2
-
27
-
-
0031627537
-
Genomic subtypes of hepatitis C virus: Epidemiology, diagnosis and clinical consequences
-
French
-
Nousbaum JB. Genomic subtypes of hepatitis C virus: epidemiology, diagnosis and clinical consequences. Bull Soc Pathol Exot. 1998;91(1): 29-33. French.
-
(1998)
Bull Soc Pathol Exot.
, vol.91
, Issue.1
, pp. 29-33
-
-
Nousbaum, J.B.1
-
28
-
-
84855215941
-
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines
-
European Association of the Study of the Liver
-
European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8.
-
(2012)
Liver Int.
, vol.32
, Issue.SUPPL. 1
, pp. 2-8
-
-
-
29
-
-
35448974936
-
Antiviral therapy: Chronic hepatitis C
-
Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat. 2007;14 Suppl 1:82-88.
-
(2007)
J Viral Hepat.
, vol.14
, Issue.SUPPL. 1
, pp. 82-88
-
-
Heathcote, E.J.1
-
30
-
-
79959478969
-
Clinical practice. Chronic hepatitis C infection
-
Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-2438.
-
(2011)
N Engl J Med.
, vol.364
, Issue.25
, pp. 2429-2438
-
-
Rosen, H.R.1
-
31
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44(1):97-103.
-
(2006)
J Hepatol.
, vol.44
, Issue.1
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
-
32
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43(5):954-960.
-
(2006)
Hepatology.
, vol.43
, Issue.5
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
-
33
-
-
33746564989
-
Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
-
Sanchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131(2):451-460.
-
(2006)
Gastroenterology.
, vol.131
, Issue.2
, pp. 451-460
-
-
Sanchez-Tapias, J.M.1
Diago, M.2
Escartín, P.3
-
34
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 with rapid virological response
-
Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 with rapid virological response. Gastroenterology. 2008;135(2):451-458.
-
(2008)
Gastroenterology.
, vol.135
, Issue.2
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
-
35
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepattis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepattis C virus infection. N Engl J Med. 2002;347(13):975-982.
-
(2002)
N Engl J Med.
, vol.347
, Issue.13
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
36
-
-
67650480397
-
Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection
-
Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051-1055.
-
(2009)
Liver Int.
, vol.29
, Issue.7
, pp. 1051-1055
-
-
Alvarez-Uria, G.1
Day, J.N.2
Nasir, A.J.3
Russell, S.K.4
Vilar, F.J.5
-
37
-
-
69949160228
-
Incidence of hepatitis C in drug injectors: The role of homelessness, opiate substitution treatment, equipment sharing, and community size
-
Craine N, Hickman M, Parry JV, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137(9):1255-1265.
-
(2009)
Epidemiol Infect.
, vol.137
, Issue.9
, pp. 1255-1265
-
-
Craine, N.1
Hickman, M.2
Parry, J.V.3
-
38
-
-
80055084488
-
Oral substitution treatment of injecting opioid users for prevention of HIV infection
-
Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.
-
(2011)
Cochrane Database Syst Rev.
, vol.8
-
-
Gowing, L.1
Farrell, M.F.2
Bornemann, R.3
Sullivan, L.E.4
Ali, R.5
-
39
-
-
79957930147
-
A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs
-
Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74-83.
-
(2011)
J Infect Dis.
, vol.204
, Issue.1
, pp. 74-83
-
-
Hagan, H.1
Pouget, E.R.2
Des Jarlais, D.C.3
-
40
-
-
80053581086
-
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence
-
Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-1988.
-
(2011)
Addiction.
, vol.106
, Issue.11
, pp. 1978-1988
-
-
Turner, K.M.1
Hutchinson, S.2
Vickerman, P.3
-
41
-
-
84861224989
-
Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-implications for intervention impact
-
Vickerman P, Martin NK, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-implications for intervention impact. Drug Alcohol Depend. 2012;123(1-3):122-131.
-
(2012)
Drug Alcohol Depend.
, vol.123
, Issue.1-3
, pp. 122-131
-
-
Vickerman, P.1
Martin, N.K.2
Hickman, M.3
-
42
-
-
84867206056
-
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings
-
Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984-1995.
-
(2012)
Addiction.
, vol.107
, Issue.11
, pp. 1984-1995
-
-
Vickerman, P.1
Martin, N.2
Turner, K.3
Hickman, M.4
-
43
-
-
79956066416
-
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility
-
Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-1144.
-
(2011)
J Hepatol.
, vol.54
, Issue.6
, pp. 1137-1144
-
-
Martin, N.K.1
Vickerman, P.2
Foster, G.R.3
Hutchinson, S.J.4
Goldberg, D.J.5
Hickman, M.6
-
44
-
-
84884365834
-
Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements
-
June 27, [Epub ahead of print.]
-
Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. June 27, 2013. [Epub ahead of print.]
-
(2013)
Clin Infect Dis.
-
-
Grebely, J.1
Matthews, G.V.2
Lloyd, A.R.3
Dore, G.J.4
-
45
-
-
79251532744
-
Mathematical modelling of hepatitis C treatment for injecting drug users
-
Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011;274(1): 58-66.
-
(2011)
J Theor Biol.
, vol.274
, Issue.1
, pp. 58-66
-
-
Martin, N.K.1
Vickerman, P.2
Hickman, M.3
-
46
-
-
78651469588
-
Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere
-
Vickerman P, Martin N, Hickman M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2010;113(2-3):83-85.
-
(2010)
Drug Alcohol Depend.
, vol.113
, Issue.2-3
, pp. 83-85
-
-
Vickerman, P.1
Martin, N.2
Hickman, M.3
-
47
-
-
77954658245
-
Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs
-
Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010;110(3):228-233.
-
(2010)
Drug Alcohol Depend.
, vol.110
, Issue.3
, pp. 228-233
-
-
Zeiler, I.1
Langlands, T.2
Murray, J.M.3
Ritter, A.4
-
48
-
-
84155180685
-
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
-
Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-57.
-
(2012)
Hepatology.
, vol.55
, Issue.1
, pp. 49-57
-
-
Martin, N.K.1
Vickerman, P.2
Miners, A.3
-
49
-
-
33947106652
-
Referral for chronic hepatitis C treatment from a drug dependency treatment setting
-
Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007;88(1):49-53.
-
(2007)
Drug Alcohol Depend.
, vol.88
, Issue.1
, pp. 49-53
-
-
Hallinan, R.1
Byrne, A.2
Agho, K.3
Dore, G.J.4
-
50
-
-
78650773812
-
Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project
-
Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23(1):23-31.
-
(2011)
Eur J Gastroenterol Hepatol.
, vol.23
, Issue.1
, pp. 23-31
-
-
Lindenburg, C.E.1
Lambers, F.A.2
Urbanus, A.T.3
-
51
-
-
76649140825
-
Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support
-
Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270-277.
-
(2010)
Eur J Gastroenterol Hepatol.
, vol.22
, Issue.3
, pp. 270-277
-
-
Grebely, J.1
Knight, E.2
Genoway, K.A.3
-
52
-
-
77954413120
-
Successful integration of hepatitis C evaluation and treatment services with methadone maintenance
-
Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1):20-26.
-
(2010)
J Addict Med.
, vol.4
, Issue.1
, pp. 20-26
-
-
Harris Jr., K.A.1
Arnsten, J.H.2
Litwin, A.H.3
-
53
-
-
77649182326
-
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
-
Grebely J, Petoumenos K, Matthews GV, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend. 2010;107(2-3):244-249.
-
(2010)
Drug Alcohol Depend.
, vol.107
, Issue.2-3
, pp. 244-249
-
-
Grebely, J.1
Petoumenos, K.2
Matthews, G.V.3
-
54
-
-
84870793129
-
Referral of intravenous drug users for antiviral treatment: Effectiveness of hepatitis C case-finding programmes
-
Gazdag G, Horváth G, Szabó O, Ungvari GS. Referral of intravenous drug users for antiviral treatment: effectiveness of hepatitis C case-finding programmes. Cent Eur J Public Health. 2012;20(3):223-225.
-
(2012)
Cent Eur J Public Health.
, vol.20
, Issue.3
, pp. 223-225
-
-
Gazdag, G.1
Horváth, G.2
Szabó, O.3
Ungvari, G.S.4
-
55
-
-
83655165142
-
Motivácia na liečbu hepatitídy C u užívatelóv psychoaktívnych látok. [Motivation for treatment of HCV infection among drug users]
-
Slovak
-
Slezáková S, Okruhlica L. Motivácia na liečbu hepatitídy C u užívatelóv psychoaktívnych látok. [Motivation for treatment of HCV infection among drug users]. Adiktologie. 2011;11(3):142-146. Slovak.
-
(2011)
Adiktologie.
, vol.11
, Issue.3
, pp. 142-146
-
-
Slezáková, S.1
Okruhlica, L.2
-
56
-
-
34548536278
-
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection
-
Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18(5): 437-443.
-
(2007)
Int J Drug Policy.
, vol.18
, Issue.5
, pp. 437-443
-
-
Grebely, J.1
Genoway, K.2
Khara, M.3
-
57
-
-
34548508918
-
The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection
-
Hopwood M, Treloar C. The drugs that dare not speak their name: injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy. 2007;18(5):374-380.
-
(2007)
Int J Drug Policy.
, vol.18
, Issue.5
, pp. 374-380
-
-
Hopwood, M.1
Treloar, C.2
-
58
-
-
77957988312
-
"We fear the police, and the police fear us": Structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine
-
Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. "We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305-1313.
-
(2010)
AIDS Care.
, vol.22
, Issue.11
, pp. 1305-1313
-
-
Mimiaga, M.J.1
Safren, S.A.2
Dvoryak, S.3
Reisner, S.L.4
Needle, R.5
Woody, G.6
-
59
-
-
77951800161
-
Policing drug users in Russia: Risk, fear, and structural violence
-
Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813-864.
-
(2010)
Subst Use Misuse.
, vol.45
, Issue.6
, pp. 813-864
-
-
Sarang, A.1
Rhodes, T.2
Sheon, N.3
Page, K.4
-
60
-
-
84859815932
-
Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision
-
Cooper CL, Giordano C, Mackie D, Mills EJ. Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag. 2010;6:207-212.
-
(2010)
Ther Clin Risk Manag.
, vol.6
, pp. 207-212
-
-
Cooper, C.L.1
Giordano, C.2
McKie, D.3
Mills, E.J.4
-
61
-
-
84873586783
-
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels
-
Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:S19-S25.
-
(2013)
J Infect Dis.
, vol.207
, Issue.SUPPL. 1
-
-
Grebely, J.1
Oser, M.2
Taylor, L.E.3
Dore, G.J.4
-
62
-
-
84856267331
-
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus
-
Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011;17(9):685-694.
-
(2011)
J Manag Care Pharm.
, vol.17
, Issue.9
, pp. 685-694
-
-
Tungol, A.1
Rademacher, K.2
Schafer, J.A.3
-
63
-
-
84865414920
-
New pharmacotherapy for hepatitis C
-
Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clin Pharmacol Ther. 2012;92(3):294-305.
-
(2012)
Clin Pharmacol Ther.
, vol.92
, Issue.3
, pp. 294-305
-
-
Assis, D.N.1
Lim, J.K.2
-
64
-
-
84886046576
-
New agents for hepatitis C and the challenges in treating co-infected patients
-
Rockstroh J. New agents for hepatitis C and the challenges in treating co-infected patients. J Int AIDS Soc. 2012;15(6):18115.
-
(2012)
J Int AIDS Soc.
, vol.15
, Issue.6
, pp. 18115
-
-
Rockstroh, J.1
-
65
-
-
33748584922
-
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
-
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006;18(10):1057-1063.
-
(2006)
Eur J Gastroenterol Hepatol.
, vol.18
, Issue.10
, pp. 1057-1063
-
-
Sylvestre, D.L.1
Clements, B.J.2
Malibu, Y.3
-
66
-
-
79955871966
-
Physicianś attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada
-
Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicianś attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol. 2011;25(3):135-139.
-
(2011)
Can J Gastroenterol.
, vol.25
, Issue.3
, pp. 135-139
-
-
Myles, A.1
Mugford, G.J.2
Zhao, J.3
Krahn, M.4
Wang, P.P.5
-
67
-
-
35248887678
-
Hepatitis C management by addiction medicine physicians: Results from a national survey
-
Litwin AH, Kunins HV, Berg KM, et al. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat. 2007;33(1):99-105.
-
(2007)
J Subst Abuse Treat.
, vol.33
, Issue.1
, pp. 99-105
-
-
Litwin, A.H.1
Kunins, H.V.2
Berg, K.M.3
-
68
-
-
84864243591
-
Léčba VHC u injekčních uživatelů drog v ČR-průzkum mezi centry pro léčbu virových hepatitid. [HCV Treatment of Injecting Drug Users in the Czech Republic-Survey among Viral Hepatitis Treatment Centres]
-
Czech
-
Mravčík V. Léčba VHC u injekčních uživatelů drog v ČR-průzkum mezi centry pro léčbu virových hepatitid. [HCV Treatment of Injecting Drug Users in the Czech Republic-Survey among Viral Hepatitis Treatment Centres]. Adiktologie. 2012;12(1): 10-22. Czech.
-
(2012)
Adiktologie.
, vol.12
, Issue.1
, pp. 10-22
-
-
Mravčík, V.1
-
69
-
-
18444397492
-
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
-
Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8(1): 45-49.
-
(2002)
Eur Addict Res.
, vol.8
, Issue.1
, pp. 45-49
-
-
Dalgard, O.1
Bjoro, K.2
Hellum, K.3
-
70
-
-
84859164566
-
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
-
Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2011;55(4):1058-1069.
-
(2011)
Hepatology.
, vol.55
, Issue.4
, pp. 1058-1069
-
-
Grebely, J.1
Pham, S.T.2
Matthews, G.V.3
-
71
-
-
0036829486
-
Prevention and treatment of hepatitis C in injection drug users
-
Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 Suppl 1):S210-S219.
-
(2002)
Hepatology.
, vol.36
, Issue.5 SUPPL. 1
-
-
Edlin, B.R.1
-
72
-
-
84873047820
-
Why is greater medication adherence associated with better outcomes
-
Hartz A, He T. Why is greater medication adherence associated with better outcomes. Emerg Themes Epidemiol. 2013;10(1):1.
-
(2013)
Emerg Themes Epidemiol.
, vol.10
, Issue.1
, pp. 1
-
-
Hartz, A.1
He, T.2
-
73
-
-
67449086883
-
Review article: Adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research
-
Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009;30(1):14-27.
-
(2009)
Aliment Pharmacol Ther.
, vol.30
, Issue.1
, pp. 14-27
-
-
Weiss, J.J.1
Brau, N.2
Stivala, A.3
Swan, T.4
Fishbein, D.5
-
74
-
-
79958807454
-
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
-
ATAHC Study Group
-
Grebely J, Matthews GV, Hellard M, et al; ATAHC Study Group. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76-85.
-
(2011)
J Hepatol.
, vol.55
, Issue.1
, pp. 76-85
-
-
Grebely, J.1
Matthews, G.V.2
Hellard, M.3
-
75
-
-
33144489685
-
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes
-
Robaeys G, Van Vlierberghe H, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18(2):159-166.
-
(2006)
Eur J Gastroenterol Hepatol.
, vol.18
, Issue.2
, pp. 159-166
-
-
Robaeys, G.1
Van Vlierberghe, H.2
Mathei, C.3
-
76
-
-
77955466100
-
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: Results of a prospective cohort study
-
Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22(9):1050-1057.
-
(2010)
Eur J Gastroenterol Hepatol.
, vol.22
, Issue.9
, pp. 1050-1057
-
-
Melin, P.1
Chousterman, M.2
Fontanges, T.3
-
77
-
-
36348986800
-
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects
-
Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991-998.
-
(2007)
Hepatology.
, vol.46
, Issue.4
, pp. 991-998
-
-
Schaefer, M.1
Hinzpeter, A.2
Mohmand, A.3
-
78
-
-
70349754174
-
High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin
-
Gazdik F, Gazdikova K, Laktis K, et al. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratisl Lek Listy. 2009;110(2):77-84.
-
(2009)
Bratisl Lek Listy.
, vol.110
, Issue.2
, pp. 77-84
-
-
Gazdik, F.1
Gazdikova, K.2
Laktis, K.3
-
79
-
-
77953024803
-
Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance
-
Schulte B, Schütt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109(1-3):248-251.
-
(2010)
Drug Alcohol Depend.
, vol.109
, Issue.1-3
, pp. 248-251
-
-
Schulte, B.1
Schütt, S.2
Brack, J.3
-
80
-
-
67651083226
-
Hepatitis C treatment for injection drug users: A review of the available evidence
-
Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561-573.
-
(2009)
Clin Infect Dis.
, vol.49
, Issue.4
, pp. 561-573
-
-
Hellard, M.1
Sacks-Davis, R.2
Gold, J.3
-
81
-
-
84874781548
-
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis
-
Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2012;55(6):806-816.
-
(2012)
Clin Infect Dis.
, vol.55
, Issue.6
, pp. 806-816
-
-
Dimova, R.B.1
Zeremski, M.2
Jacobson, I.M.3
Hagan, H.4
Des Jarlais, D.C.5
Talal, A.H.6
-
82
-
-
72249093341
-
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
-
Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123-135.
-
(2010)
Gastroenterology.
, vol.138
, Issue.1
, pp. 123-135
-
-
Dore, G.J.1
Hellard, M.2
Matthews, G.V.3
-
83
-
-
34547942089
-
Adherence to hepatitis C treatment in recovering heroin users maintained on methadone
-
Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741-747.
-
(2007)
Eur J Gastroenterol Hepatol.
, vol.19
, Issue.9
, pp. 741-747
-
-
Sylvestre, D.L.1
Clements, B.J.2
-
84
-
-
20144388420
-
Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries
-
Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis. 2005;40 Suppl 5:373-378.
-
(2005)
Clin Infect Dis.
, vol.40
, Issue.SUPPL. 5
, pp. 373-378
-
-
Reimer, J.1
Schulte, B.2
Castells, X.3
-
85
-
-
84855215941
-
European Association of the Study of the Liver hepatitis C virus clinical practice guidelines
-
Calvaruso V, Craxi A. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8.
-
(2012)
Liver Int.
, vol.32
, Issue.SUPPL. 1
, pp. 2-8
-
-
Calvaruso, V.1
Craxi, A.2
-
86
-
-
84880966007
-
Recommendations for the management of hepatitis C virus infection among people who inject drugs
-
International Network on Hepatitis in Substance Users
-
Robaeys G, Grebely J, Mauss S, et al; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129-S137.
-
(2013)
Clin Infect Dis.
, vol.57
, Issue.SUPPL. 2
-
-
Robaeys, G.1
Grebely, J.2
Mauss, S.3
-
87
-
-
0034956562
-
Treatment of hepatitis C infection in injection drug users
-
Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34(1): 188-193.
-
(2001)
Hepatology.
, vol.34
, Issue.1
, pp. 188-193
-
-
Backmund, M.1
Meyer, K.2
Von Zielonka, M.3
Eichenlaub, D.4
-
88
-
-
67149143393
-
Need-adapted HCV-treatment setting for injection drug users
-
Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet. 2009;373(9681):2090-2091.
-
(2009)
Lancet.
, vol.373
, Issue.9681
, pp. 2090-2091
-
-
Reimer, J.1
Haasen, C.2
-
89
-
-
34548481302
-
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study
-
Nguyen OK, Dore GJ, Kaldor JM, Hellard ME. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. Int J Drug Policy. 2007;18(5): 447-451.
-
(2007)
Int J Drug Policy.
, vol.18
, Issue.5
, pp. 447-451
-
-
Nguyen, O.K.1
Dore, G.J.2
Kaldor, J.M.3
Hellard, M.E.4
-
90
-
-
78649243992
-
Uptake and delivery of C treatment in opiate substitution treatment: Perceptions of clients and health professionals
-
Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010;17(12): 839-844.
-
(2010)
J Viral Hepat.
, vol.17
, Issue.12
, pp. 839-844
-
-
Treloar, C.1
Newland, J.2
Rance, J.3
Hopwood, M.4
-
91
-
-
38949197759
-
Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service
-
Teasdale KE, Keren KM, Kiel A, Becker K. Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service. Drug Alcohol Rev. 2008;27(2):152-159.
-
(2008)
Drug Alcohol Rev.
, vol.27
, Issue.2
, pp. 152-159
-
-
Teasdale, K.E.1
Keren, K.M.2
Kiel, A.3
Becker, K.4
-
92
-
-
16844376913
-
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities
-
Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005;40 Suppl 5:S339-S345.
-
(2005)
Clin Infect Dis.
, vol.40
, Issue.SUPPL. 5
-
-
Litwin, A.H.1
Soloway, I.2
Gourevitch, M.N.3
-
93
-
-
77955370219
-
Factors to improve the management of hepatitis C in drug users: An observational study in an addiction centre
-
pii261472
-
Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010:pii261472.
-
(2010)
Gastroenterol Res Pract. 2010
-
-
Moussalli, J.1
Delaquaize, H.2
Boubilley, D.3
-
94
-
-
16844374761
-
Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection
-
Hagan H, Strauss SM, Astone JM, Des Jarlais DC. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis. 2005;40 Suppl 5:S297-S303.
-
(2005)
Clin Infect Dis.
, vol.40
, Issue.SUPPL. 5
-
-
Hagan, H.1
Strauss, S.M.2
Astone, J.M.3
Des Jarlais, D.C.4
-
95
-
-
0038350461
-
Gaps in the drug-free and methadone treatment program response to hepatitis C
-
Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H. Gaps in the drug-free and methadone treatment program response to hepatitis C. J Subst Abuse Treat. 2003;24(4):291-297.
-
(2003)
J Subst Abuse Treat.
, vol.24
, Issue.4
, pp. 291-297
-
-
Strauss, S.M.1
Astone, J.2
Vassilev, Z.P.3
Des Jarlais, D.C.4
Hagan, H.5
-
96
-
-
0036202472
-
A nationwide survey of hepatitis C services provided by drug treatment programs
-
Strauss SM, Falkin GP, Vassilev Z, Des Jarlais DC, Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat. 2002;22(2):55-62.
-
(2002)
J Subst Abuse Treat.
, vol.22
, Issue.2
, pp. 55-62
-
-
Strauss, S.M.1
Falkin, G.P.2
Vassilev, Z.3
Des Jarlais, D.C.4
Astone, J.5
-
97
-
-
0035913261
-
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
-
Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345(3): 211-215.
-
(2001)
N Engl J Med.
, vol.345
, Issue.3
, pp. 211-215
-
-
Edlin, B.R.1
Seal, K.H.2
Lorvick, J.3
-
98
-
-
33845283877
-
Hepatitis C in Australia: Impact of a mass media campaign
-
Smith BJ, Bauman AE, Chen J, et al. Hepatitis C in Australia: impact of a mass media campaign. Am J Prev Med. 2006;31(6):492-498.
-
(2006)
Am J Prev Med.
, vol.31
, Issue.6
, pp. 492-498
-
-
Smith, B.J.1
Bauman, A.E.2
Chen, J.3
-
99
-
-
0028137673
-
Syringe and needle exchange as HIV/AIDS prevention for injection drug users
-
Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115-120.
-
(1994)
JAMA.
, vol.271
, Issue.2
, pp. 115-120
-
-
Watters, J.K.1
Estilo, M.J.2
Clark, G.L.3
Lorvick, J.4
-
100
-
-
0032529426
-
Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992-1995
-
Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992-1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):505-511.
-
(1998)
J Acquir Immune Defic Syndr Hum Retrovirol.
, vol.18
, Issue.5
, pp. 505-511
-
-
Bluthenthal, R.N.1
Kral, A.H.2
Erringer, E.A.3
Edlin, B.R.4
-
101
-
-
0034119211
-
The effect of syringe exchange use on high-risk injection drug users: A cohort study
-
Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605-611.
-
(2000)
AIDS.
, vol.14
, Issue.5
, pp. 605-611
-
-
Bluthenthal, R.N.1
Kral, A.H.2
Gee, L.3
Erringer, E.A.4
Edlin, B.R.5
-
102
-
-
0038575483
-
Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
-
Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80-88.
-
(2003)
Gastroenterology.
, vol.125
, Issue.1
, pp. 80-88
-
-
Gerlach, J.T.1
Diepolder, H.M.2
Zachoval, R.3
-
103
-
-
33644501853
-
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study
-
Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250-256.
-
(2006)
Hepatology.
, vol.43
, Issue.2
, pp. 250-256
-
-
Wiegand, J.1
Buggisch, P.2
Boecher, W.3
-
104
-
-
37049001443
-
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users
-
Grebely J, Genoway KA, Raffa JD et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence. 2008;93;(1-2):141-147.
-
(2008)
Drug and Alcohol Dependence.
, vol.93
, Issue.1-2
, pp. 141-147
-
-
Grebely, J.1
Genoway, K.A.2
Raffa, J.D.3
-
105
-
-
69249227492
-
Hepatitis C treatment in patients with drug addiction: Clinical management of interferon-alpha-associated psychiatric side effects
-
Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev. 2008;(2):177-187.
-
(2008)
Curr Drug Abuse Rev.
, Issue.2
, pp. 177-187
-
-
Schaefer, M.1
Mauss, S.2
|